BusinessBeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian CancerBy Nasdaq OMXDec 18, 2017, 11:00 AM UTC
BusinessBeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 CongressBy Nasdaq OMXSep 8, 2017, 10:00 AM UTC
BusinessBeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual MeetingBy Nasdaq OMXApr 21, 2017, 11:00 AM UTC
BusinessBeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290By Nasdaq OMXDec 21, 2016, 9:15 PM UTC
